4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Short Interest Update

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) was the target of a significant increase in short interest in December. As of December 31st, there was short interest totaling 8,677,770 shares, an increase of 72.7% from the December 15th total of 5,023,933 shares. Currently, 16.8% of the company’s stock are short sold. Based on an average trading volume of 1,473,096 shares, the days-to-cover ratio is currently 5.9 days. Based on an average trading volume of 1,473,096 shares, the days-to-cover ratio is currently 5.9 days. Currently, 16.8% of the company’s stock are short sold.

Insider Buying and Selling

In other 4D Molecular Therapeutics news, insider Scott Bizily sold 2,678 shares of the firm’s stock in a transaction on Friday, October 24th. The shares were sold at an average price of $12.00, for a total value of $32,136.00. Following the completion of the sale, the insider directly owned 3,594 shares in the company, valued at approximately $43,128. This trade represents a 42.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold 6,337 shares of company stock valued at $70,649 in the last ninety days. Company insiders own 9.60% of the company’s stock.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Dynamic Technology Lab Private Ltd purchased a new position in shares of 4D Molecular Therapeutics in the first quarter worth about $39,000. Wexford Capital LP bought a new position in 4D Molecular Therapeutics in the 3rd quarter worth approximately $41,000. Los Angeles Capital Management LLC purchased a new position in 4D Molecular Therapeutics in the 2nd quarter valued at approximately $42,000. Quadrature Capital Ltd purchased a new position in 4D Molecular Therapeutics in the 2nd quarter valued at approximately $42,000. Finally, Farther Finance Advisors LLC raised its holdings in 4D Molecular Therapeutics by 117.4% during the 3rd quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock valued at $43,000 after acquiring an additional 2,674 shares during the period. 99.27% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts recently commented on FDMT shares. Wall Street Zen lowered 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 6th. Morgan Stanley upgraded 4D Molecular Therapeutics from an “underweight” rating to an “equal weight” rating in a report on Friday, November 7th. Leerink Partners restated an “outperform” rating and set a $17.00 price target on shares of 4D Molecular Therapeutics in a research note on Friday, October 31st. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, January 7th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Wednesday, October 8th. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $33.25.

4D Molecular Therapeutics Stock Down 10.0%

FDMT traded down $0.88 during trading on Thursday, hitting $7.89. 409,510 shares of the company traded hands, compared to its average volume of 811,539. 4D Molecular Therapeutics has a one year low of $2.23 and a one year high of $12.34. The stock’s fifty day moving average is $9.58 and its 200 day moving average is $7.98. The firm has a market cap of $450.51 million, a P/E ratio of -2.11 and a beta of 2.99.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings results on Monday, November 10th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.02) by $0.01. 4D Molecular Therapeutics had a negative net margin of 174,314.17% and a negative return on equity of 47.27%. The company had revenue of $0.09 million during the quarter, compared to analyst estimates of $0.40 million. On average, equities research analysts forecast that 4D Molecular Therapeutics will post -2.84 EPS for the current fiscal year.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.